Insights

Gathering insights about Atrium…

Similar companies to Atrium

Atrium Tech Stack

Atrium uses 8 technology products and services including Open Graph, Twemoji, Lightbox, and more. Explore Atrium's tech stack below.

Open Graph
Content Management System
Twemoji
Font Scripts
Lightbox
Javascript Libraries
Debian
Operating Systems
X-Content-Type-Options
Web & Portal Technology
Google Analytics
Web Analytics
GoDaddy
Web Hosting
Apache
Web Servers

Media & News

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE: BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration.
Apr 23, 2026 | www.prnewswire.com
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of seven non-executive individuals newly hired by the Company. The employees received, in the aggregate, non-qualified stock options to purchase 101,250 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $14.30 per share, the closing price of the Company's common stock as reported by Nasdaq on the effective date of the grant, 25% of which will vest and become exercisable on the first anniversary of the grant date, and the remaining underlying shares will vest in 36 substantially equal installments each month thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 50,625 shares of the Company's common stock, 25% of which will vest in the first anniversary of the grant date, and the remaining underlying shares will vest in three substantially equal installments each year thereafter, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the "Awards.
Apr 20, 2026 | www.prnewswire.com
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week Low – Here’s Why
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) shares hit a new 52-week low on Saturday. The company traded as low as $13.06 and last traded at $14.75, with a volume of 7932167 shares changing hands. The stock had previously closed at $14.58. Analyst Ratings Changes A number of analysts have commented on RNA
Mar 02, 2026 | www.defenseworld.net
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectively SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. Atrium Therapeutics was established in connection with Avidity Biosciences, Inc.'s acquisition by Novartis AG.
Feb 27, 2026 | www.prnewswire.com
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that the company will be presenting one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 8-11, 2026, in Orlando, Florida. 2026 MDA Clinical & Scientific Congress Presentations Oral Presentation: Del-zota Treatment is Associated with Near Normalization of CK Levels and Improvements in Key Functional Outcomes at 1 Year in Participants with DMD44 (March 11, 2026: 12:30 p.m.
Feb 26, 2026 | www.prnewswire.com
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that it intends to convene its upcoming special meeting of stockholders (the "Special Meeting") scheduled for February 23, 2026, at 10:00 a.m., Eastern time, and then immediately adjourn proceedings, without conducting any other business.
Feb 23, 2026 | www.prnewswire.com
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicing Treatment demonstrated improvements in multiple measures including myotonia, muscle function and strength, mobility and patient-reported outcomes Del-desiran showed acceptable safety and tolerability with most adverse events mild or moderate SAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the final results from the completed Phase 1/2 MARINA® trial of delpacibart etedesiran (del-desiran) in people living with myotonic dystrophy type 1 (DM1) will be published in the February 19 issue of The New England Journal of Medicine (NEJM). The manuscript is titled "An Antibody Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.
Feb 18, 2026 | www.prnewswire.com

Atrium's Email Address Formats

Atrium uses at least 1 format(s):

Atrium Email Formats	Example	Percentage
First.Last@atrium.com	John.Doe@atrium.com	93%
First@atrium.com	John@atrium.com	5%
FLast@atrium.com	JDoe@atrium.com	1%
First.Middle@atrium.com	John.Michael@atrium.com	1%

Frequently Asked Questions

Where is Atrium's headquarters located?

Atrium's main headquarters is located at 3890 W Northwest Highway Suite 500 Dallas, TX 75220 US. The company has employees across 6 continents, including North AmericaEuropeAsia.

What is Atrium's stock symbol?

Atrium is a publicly traded company; the company's stock symbol is RNA.

What is Atrium's official website and social media links?

Atrium's official website is atrium.com and has social profiles on LinkedIn.

What is Atrium's NAICS code?

Atrium's NAICS code is 4233 - Lumber and Other Construction Materials Merchant Wholesalers.

How many employees does Atrium have currently?

As of July 2019, Atrium has approximately 1K employees across 6 continents, including North AmericaEuropeAsia. Key team members include Owner: G. K.Marketing Manager: K. P.General Counsel: G. C.. Explore Atrium's employee directory with LeadIQ.

What industry does Atrium belong to?

Atrium operates in the Wholesale Building Materials industry.

What technology does Atrium use?

Atrium's tech stack includes Open GraphTwemojiLightboxDebianX-Content-Type-OptionsGoogle AnalyticsGoDaddyApache.

What is Atrium's email format?

Atrium's email format typically follows the pattern of First.Last@atrium.com. Find more Atrium email formats with LeadIQ.

When was Atrium founded?

Atrium was founded in 1948.

Atrium

Q: What is Atrium's official website and social media links?

Atrium's official website is atrium.com. Atrium has social profiles on LinkedIn.

Q: How many employees does Atrium have currently?

Atrium has approximately 1K employees.

Q: What technology does Atrium use?

Atrium's tech stack includes oEmbed, Module Federation, Gravity Forms, X-XSS-Protection, Font Awesome.

Q: What is Atrium's NAICS code?

Atrium's NAICS code is 4233 (Lumber and Other Construction Materials Merchant Wholesalers).

Wholesale Building MaterialsTexas, United States1001-5000 Employees

For more than 50 years, Atrium Corporation has offered the highest quality window and door products to builders, contractors and distributors in the residential construction industry. Dedicated to meeting the needs of its customers, the Atrium family of brands provides a versatile range of window and patio door products, including vinyl and aluminum models, as well as replacement and new construction product lines.

Company Overview

Headquarters: 3890 W Northwest Highway Suite 500 Dallas, TX 75220 US
Website: atrium.com
Stock Symbol: RNA
NAICS Code: 4233 - Lumber and Other Construction Materials Merchant Wholesalers
Founded: 1948
Employees: 1001-5000

Media & News

Funding & Financials

$10M
Atrium's revenue is estimated to be in the range of $10M

Funding & Financials

$10M
Atrium's revenue is estimated to be in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Atrium

Legl

Heymarket

Lawmatics

NextChapter

Level

Onestop

Everlaw

Lawline

Paladin

PracticePanther

Atrium Tech Stack

Media & News

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week Low – Here’s Why

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Atrium's Email Address Formats

Frequently Asked Questions

Where is Atrium's headquarters located?

What is Atrium's stock symbol?

What is Atrium's official website and social media links?

What is Atrium's NAICS code?

How many employees does Atrium have currently?

What industry does Atrium belong to?

What technology does Atrium use?

What is Atrium's email format?

When was Atrium founded?

Atrium

Company Overview

Media & News

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week Low – Here’s Why

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?